Astellas Pharma

Naoki Okamura, Representative Director, President and CEO, guides Astellas's five-year Corporate Strategic Plan (CSP2026). The plan governs R&D focus, therapeutic-area selection, and capital allocation. Astellas's board and top management set investment posture as detailed in the annual Integrated Report.

Astellas runs an open-innovation network called SakuLab with wet-lab sites in Tsukuba and Cambridge. The firm also operates the TME iLab for tumor-microenvironment research and a digital-health Rx+ Business Accelerator. These hubs complement internal drug-discovery capabilities and clinical-stage partnerships.

Astellas is a publicly traded pharmaceutical company, not a family office. It generates revenue from commercialized medicines and reinvests through an R&D pipeline. The firm is listed on the Tokyo Stock Exchange and operates more than 70 countries.

Astellas concentrates on five areas: oncology, ophthalmology, urology, immunology, and women's health. Its R&D pipeline further focuses on blindness and regeneration, genetic regulation, immuno-oncology, and targeted protein degradation.

Yes, the Astellas Global Health Foundation runs separately from the pharmaceutical business. It handles charitable funding and global-health access programs, while Astellas's social-impact reporting appears in its integrated annual review.

CSP2026 structures resource allocation around pipeline milestones, therapeutic focus areas, and digital-transformation goals. The plan aims to position Astellas as a sustainable growth company and ties non-financial metrics — such as AI-enhanced drug discovery — directly to investment decisions.

Its distributed R&D model pairs internal discovery engines with SakuLab open-innovation sites and digital-health accelerators like HealthX. This architecture enables simultaneous push into targeted protein degradation, gene therapy, and AI-driven drug design, governed by a five-year strategic cycle.